Mild cognitive impairment (MCI) and dementia are clinically prevalent in the elderly. There is a high risk of cognitive decline in patients diagnosed with MCI or dementia. This review describes the effectiveness of Ginkgo biloba leaf special extract EGb 761(R) for the treatment of dementia syndromes and EGb 761(R) combination therapy with other medications for symptomatic dementia. This drug has shown convincing results, improving cognitive function, neuropsychiatric symptoms and consequent reduction of caregiver stress and maintenance of autonomy in patients with age-related cognitive decline, MCI and mild to moderate dementia. Currently, there is little evidence to support the combination therapy with anti-dementia drugs and, therefore, more evidence is needed to evaluate the role of EGb 761(R) in mixed therapy.

Mild cognitive impairment and mild dementia: The role of ginkgo biloba (EGb 761®) / Tomino, C.; Ilari, S.; Solfrizzi, V.; Malafoglia, V.; Zilio, G.; Russo, P.; Proietti, S.; Marcolongo, F.; Scapagnini, G.; Muscoli, C.; Rossini, P. M.. - In: PHARMACEUTICALS. - ISSN 1424-8247. - 14:4(2021). [10.3390/ph14040305]

Mild cognitive impairment and mild dementia: The role of ginkgo biloba (EGb 761®)

Tomino C.;Ilari S.;Marcolongo F.;
2021

Abstract

Mild cognitive impairment (MCI) and dementia are clinically prevalent in the elderly. There is a high risk of cognitive decline in patients diagnosed with MCI or dementia. This review describes the effectiveness of Ginkgo biloba leaf special extract EGb 761(R) for the treatment of dementia syndromes and EGb 761(R) combination therapy with other medications for symptomatic dementia. This drug has shown convincing results, improving cognitive function, neuropsychiatric symptoms and consequent reduction of caregiver stress and maintenance of autonomy in patients with age-related cognitive decline, MCI and mild to moderate dementia. Currently, there is little evidence to support the combination therapy with anti-dementia drugs and, therefore, more evidence is needed to evaluate the role of EGb 761(R) in mixed therapy.
2021
alzheimer’s disease; ginkgo biloba (Egb761®); Tebonin; anti-dementia drugs; mild cognitive impairment (MCI); mild dementia; randomized controlled trials
01 Pubblicazione su rivista::01a Articolo in rivista
Mild cognitive impairment and mild dementia: The role of ginkgo biloba (EGb 761®) / Tomino, C.; Ilari, S.; Solfrizzi, V.; Malafoglia, V.; Zilio, G.; Russo, P.; Proietti, S.; Marcolongo, F.; Scapagnini, G.; Muscoli, C.; Rossini, P. M.. - In: PHARMACEUTICALS. - ISSN 1424-8247. - 14:4(2021). [10.3390/ph14040305]
File allegati a questo prodotto
File Dimensione Formato  
Tomino_Mild_cognitive_impairment_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.74 MB
Formato Adobe PDF
1.74 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1753963
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 21
social impact